Table 1. Demographic data.
| large local reaction | systemic sting reaction | p-value | |
|---|---|---|---|
| No. of patients | 310 | 310 | |
| age range (mean age) [years] | 5–84 (44) | 16–80 (47) | p = 0.008 |
| sex | |||
| male | 108 (34.8%) | 154 (49.7%) | p<0.001 |
| female | 202 (65.2%) | 156 (50.3%) | |
| Inhalant allergy | |||
| no | 196 (63.2%) | 240 (77.4%) | p<0.001 |
| yes | 114 (36.8%) | 70 (22.6%) | |
| antihypertensive treatment | |||
| no medication | 256 (82.6%) | 259 (83.5%) | p = 0.316 |
| betablocker | 13 (4.2%) | 13 (4.2%) | |
| ACE-inhibitor | 7 (2.3%) | 14 (4.5%) | |
| ATII-antagonist | 12 (3.9%) | 13 (4.2%) | |
| ACE-inhibitor + betablocker | 5 (1.6%) | 7 (2.3%) | |
| ATII-antagonist + betablocker | 11 (3.6%) | 4 (1.3%) | |
| tryptase level | |||
| ≤ 11.4μg/L | 53 (17.1%) | 284 (91.6%) | p = 0.096 |
| > 11.4μg/L | 0 (0.0%) | 20 (6.5%) | |
| sting localization | |||
| trunk | 9 (2.9%) | 46 (14.8%) | p<0.001 |
| upper extremities | 121 (39.0%) | 116 (37.4%) | |
| lower extremities | 98 (31.6%) | 75 (24.2%) | |
| head | 37 (11.9%) | 61 (19.7%) | |
| • face and lips | 34 (91.9%) | 45 (73.8%) | p = 0.035 |
| • capillitium | 3 (8.1%) | 16 (26.2%) |